RxDoctor Payments Data

Maged Boutros, MD

Internal Medicine · Clifton, NJNPI 1497785281

Payments from drug & device makers

$12,382in general payments, 2019–2025

Across 701 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Lilly USA, LLC$818
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$12,17498%
  • Education$2082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,382 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$173,349
Medicare patients
394
Services billed
1,605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$196,024
JardianceEmpagliflozin80$108,644
EliquisApixaban75$82,756
MounjaroTirzepatide67$74,578
ZenpepLipase/Protease/Amylase12$45,905
CreonLipase/Protease/Amylase21$44,458
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$31,982
VascepaIcosapent Ethyl37$27,213
JanuviaSitagliptin Phosphate20$25,382
Diclofenac Sodium62$24,124
JanumetSitagliptin Phos/Metformin Hcl17$20,768
LinzessLinaclotide26$19,063
TradjentaLinagliptin18$17,000
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$11,921
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,852$196,024148 claims
Boehringer IngelheimJardiance, Tradjenta$313$125,64498 claims
PfizerEliquis$97$82,75675 claims
Lilly USA, LLCMounjaro$818$74,57867 claims
AbbVieCreon, Linzess$803$63,52147 claims
Aimmune Therapeutics, Inc.Zenpep$55$45,90512 claims
GSKTrelegy Ellipta$1,490$31,98246 claims
AstraZenecaBreztri Aerosphere$1,251$10,15516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Clifton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →